Abstract

For many years, polyketide natural products have provided the scientific community with a rich source of novel molecular architectures, many of which have become important therapeutics for clinical use.[1] In 1993, the polyketide rhizopodin was isolated from the myxobacterium Myxococcus stipitatus.[2] It was shown to display an interesting array of biological properties, including potent anti-tumor activity against a range of cancer cell lines in the low nanomolar range and the ability to inhibit the polymerization of actin.[2,3] Despite its original structural assignment as the 19-membered monomeric lactone 1a (monorhizopodin), recent studies revealed dimeric structure 2 to be the correct architecture of rhizopodin (Figure 1).[4] These molecules have started to attract attention from the synthetic community, although no total syntheses have been reported to date.[5]

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call